Vor Biopharma Launches $150 Million Private Placement; Shares Rise

MT Newswires Live12-15

Vor Biopharma (VOR) said Monday it agreed to sell about 13.9 million shares in a private placement to institutional investors priced at $10.81 a share.

The offering is expected to raise gross proceeds of about $150 million and is slated to close on Thursday, the company said.

The financing includes participation from RA Capital Management, Forbion, Frazier Life Sciences, Caligan Partners, Logos Capital and Venrock Healthcare Capital Partners, the company said, adding that Forbion is being granted the right to appoint one director to its board.

Vor said it plans to use the proceeds to support development of telitacicept, including its ongoing global phase 3 trial in myasthenia gravis and a planned global phase 3 trial in primary Sjogren's disease.

Vor Biopharma shares were more than 7% higher in recent trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2591647836?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-15 22:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591647836","market":"sg","top_or_hot":-1,"title":"Vor Biopharma Launches $150 Million Private Placement; Shares Rise","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/VOR\">Vor Biopharma</a> (VOR) said Monday it agreed to sell about 13.9 million shares in a private placement to institutional investors priced at $10.81 a share.</p><p>The offering is expected to raise gross proceeds of about $150 million and is slated to close on Thursday, the company said.</p><p>The financing includes participation from RA Capital Management, Forbion, Frazier Life Sciences, Caligan Partners, Logos Capital and Venrock Healthcare Capital Partners, the company said, adding that Forbion is being granted the right to appoint one director to its board.</p><p>Vor said it plans to use the proceeds to support development of telitacicept, including its ongoing global phase 3 trial in myasthenia gravis and a planned global phase 3 trial in primary Sjogren's disease.</p><p>Vor Biopharma shares were more than 7% higher in recent trading.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vor Biopharma Launches $150 Million Private Placement; Shares Rise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVor Biopharma Launches $150 Million Private Placement; Shares Rise\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-15 22:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/VOR\">Vor Biopharma</a> (VOR) said Monday it agreed to sell about 13.9 million shares in a private placement to institutional investors priced at $10.81 a share.</p><p>The offering is expected to raise gross proceeds of about $150 million and is slated to close on Thursday, the company said.</p><p>The financing includes participation from RA Capital Management, Forbion, Frazier Life Sciences, Caligan Partners, Logos Capital and Venrock Healthcare Capital Partners, the company said, adding that Forbion is being granted the right to appoint one director to its board.</p><p>Vor said it plans to use the proceeds to support development of telitacicept, including its ongoing global phase 3 trial in myasthenia gravis and a planned global phase 3 trial in primary Sjogren's disease.</p><p>Vor Biopharma shares were more than 7% higher in recent trading.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2591647836","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2591647836","pubTimestamp":1765809919,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Vor Biopharma  said Monday it agreed to sell about 13.9 million shares in a private placement to institutional investors priced at $10.81 a share.The offering is expected to raise gross proceeds of about $150 million and is slated to close on Thursday, the company said.The financing includes participation from RA Capital Management, Forbion, Frazier Life Sciences, Caligan Partners, Logos Capital and Venrock Healthcare Capital Partners, the company said, adding that Forbion is being granted the right to appoint one director to its board.Vor said it plans to use the proceeds to support development of telitacicept, including its ongoing global phase 3 trial in myasthenia gravis and a planned global phase 3 trial in primary Sjogren's disease.Vor Biopharma shares were more than 7% higher in recent trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","VOR":"Vor Biopharma Inc."},"translate_title":"Vor Biopharma启动1.5亿美元私募；股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VOR":1},"content_text":"Vor Biopharma (VOR) said Monday it agreed to sell about 13.9 million shares in a private placement to institutional investors priced at $10.81 a share.The offering is expected to raise gross proceeds of about $150 million and is slated to close on Thursday, the company said.The financing includes participation from RA Capital Management, Forbion, Frazier Life Sciences, Caligan Partners, Logos Capital and Venrock Healthcare Capital Partners, the company said, adding that Forbion is being granted the right to appoint one director to its board.Vor said it plans to use the proceeds to support development of telitacicept, including its ongoing global phase 3 trial in myasthenia gravis and a planned global phase 3 trial in primary Sjogren's disease.Vor Biopharma shares were more than 7% higher in recent trading.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2591647836","isCrawlerRequest":true}